A comparison of pharmacokinetics software for therapeutic drug monitoring of piperacillin in patients with severe infections.

Ana Socorro Rodríguez-BáezMaría Jiménez-MeseguerRosa Del Carmen Milán-SegoviaSilvia Romano-MorenoEmilia BarciaArturo Ortiz-ÁlvarezBenito García-DíazSusanna Edith Medellín-Garibay

Published in: European journal of hospital pharmacy : science and practice (2022)

Current software for TDM is a valuable tool, but it may also include different population pharmacokinetic models in patients with severe infections, and should be evaluated before performing a model-based TDM in clinical practice. Considering the heterogeneous characteristics of patients with severe infections, this study demonstrates the need for therapy personalisation for PIP to improve pharmacokinetic/pharmacodynamic target attainment.

Keyphrases

early onset
clinical practice
drug induced
stem cells
mesenchymal stem cells
cell therapy